MAIA Biotechnology, Inc. (MAIA)
(Real Time Quote from BATS)
$2.88 USD
+0.03 (1.05%)
Updated Sep 20, 2024 03:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
MAIA Biotechnology, Inc. [MAIA]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Significant Advancement in Potential Non-Small Cell Lung Cancer Therapy as THIO-101 Shows Enhanced Efficacy and Disease Control in Third-Line Treatment
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
THIO-101 Advancing in Phase 2 NSCLC Trials With Multiple Upcoming Milestones
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Advancements in Oncology with THIO-101 and Successful Capital Raise
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Showcases Encouraging Efficacy Profile in Preliminary Readout Compared to Standard of Care
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Q2 2023 Financial Results Reflect Pipeline Advancements
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging THIO-101 Phase 2 Trial Data and Second Patent Application Filed
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Promising Efficacy and Safety in NSCLC and HCC Reaffirms Potential
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
FY 2022 Financial Results Update and Operational Highlights
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Progress Across Multiple Clinical and Pre-Clinical Pipeline Candidates
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
Company: MAIA Biotechnology, Inc.
Industry: Medical - Biomedical and Genetics
Initiation Report-Pan-cancer Therapeutic Applications with Potential to Overcome Therapeutic Resistance
Provider: Diamond Equity Research LLC
Analyst: DIAMOND H
|